缓解易布鲁替尼布诱导的心室节律失常和心脏功能障碍与甲福林
Pengsha Li1, Daiqi Liu1, Pan Gao1
1Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Second Hospital of Tianjin Medical University Tianjin China.
Cancer innovation
|November 15, 2024
概括
甲福明通过改善心脏功能和减少心律失常,保护小鼠免受伊布鲁替尼诱导的心脏毒性. 这项研究强调了甲福明的作用.
科学领域:
- 心血管毒理学心血管毒理学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 布鲁顿的氨酸激酶抑制剂易布鲁替尼治疗B细胞癌症,但引起心脏毒性.
- 调查ibrutinib诱导的心脏毒性机制和甲福林的保护作用对于患者的安全至关重要.
研究的目的:
- 阐明易布鲁丁尼布诱导心脏毒性的机制.
- 为了评估甲福明在预防和逆转ibrutinib引起的心脏损伤方面的疗效.
主要方法:
- 雄性C57BL/6J小鼠接受了易布鲁替尼 (30毫克/公斤/天) 来诱导心脏毒性.
- 在ibrutinib. metformin (200 mg/kg/day) 开始于一周前开始使用.
- 评估了心脏功能,电生理学和分子途径 (PI3K-AKT,AMPK,亡).
主要成果:
- 易布鲁替尼诱导了心室节律失常,导电异常和减少的射出分数.
- 甲素预治疗逆转了这些心脏毒性影响.
- 易布鲁替尼降低了PI3K-AKT活性,导致心肌细胞亡;甲福林上调了AMPK和PI3K-AKT.
结论:
- 甲福明有效地减轻易布鲁丁尼引起的心脏毒性和心脏功能障碍.
- 甲胺增强AMPK和PI3K-AKT通路活性,保护心肌细胞.
- 甲福尔明在接受ibrutinib治疗的患者中显示出改善心血管安全的潜力.
相关概念视频
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
707
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
707
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
01:26Heart Failure Drugs: Inotropic Agents
523
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
523
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
391
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
911
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
911
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
782
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
782